ISA101b for Carcinoma, Squamous Cell
Study Summary
This trial will compare cemiplimab to cemiplimab plus ISA101b to see if the addition of ISA101b helps cemiplimab work better.
- Carcinoma, Squamous Cell
- HPV16 Positive
- Squamous cell carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 1 Secondary · Reporting Duration: 25months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Active ISA101b and cemiplimab.
1 of 2
Placebo and cemiplimab
1 of 2
Experimental Treatment
Non-Treatment Group
194 Total Participants · 2 Treatment Groups
Primary Treatment: ISA101b · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 6th, 2021
Last Reviewed: November 24th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Missouri | 100.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| M. D. Anderson Cancer Center | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |